ascopubs.org

Prognostic significance of MAGE-A10 and NY-ESO-1 cancer-testis antigen in breast cancer.

Development of automated quantitative multiparameter immunocytochemical profiling of circulating tumor cells (CTCs) in breast cancer (BC). This is an ASCO Meeting Abstract from the 2012 ASCO Annual ...
Business Insider

Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting

PHILADELPHIA and OXFORD, U.K., May 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will release updated data from ongoing clinical ...
Business Insider

Adaptimmune Presents Study Designs for Ongoing MAGE-A4 and NY-ESO SPEAR T-cell Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

PHILADELPHIA and OXFORD, U.K., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, is presenting two trials in progress posters ...
ascopubs.org

Two phase I/II open label clinical trials evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with ...

A phase 1b/2 study of CD30-specific chimeric antigen receptor T-cell (CAR-T) therapy in combination with bendamustine in patients with CD30+ Hodgkin and non-Hodgkin lymphoma.